Seegene Expands Its Global Presence with New Branch in France

Seegene Establishes New Branch in France

Seegene Inc., a global leader in molecular diagnostics (MDx), has announced the opening of its new branch in France. This strategic move is aimed at strengthening its presence within Europe and supports the company's global sales expansion. With this new facility, which marks Seegene's eighth foreign subsidiary, the company plans to increase local engagement with customers and partners by enhancing technical support, market development, and collaboration with healthcare stakeholders.

According to the global market research firm Grand View Research, the French molecular diagnostics market is estimated to be around €600 million, representing approximately 15% of the entire European market. France holds the position of the second largest market in Europe, closely following Germany, which accounts for 19% of the market share. There is a notably high demand for diagnostic tests related to sexually transmitted infections (STIs) and gastrointestinal (GI) infections.

Seegene is targeting to boost sales in these areas while also expanding its offerings to include testing for respiratory infections, cervical cancer, and other diagnostic types.

Daniel Shin, Executive Vice President and Head of Global Sales and Marketing at Seegene, highlighted the competitive nature of the French diagnostics market, which is predominantly private. He noted that the company’s ability to deliver products swiftly and respond to customer needs is crucial for maintaining competitiveness. The new branch will refine Seegene's orientation within the French healthcare landscape, thereby enhancing local customer service and accelerating the growth of its in vitro diagnostics business through specialized local expertise.

In addition to improving customer engagement, the new branch in France serves as a strategic launching point for Seegene's next-generation diagnostic solutions under development, including CURECA™, a fully automated and operator-free PCR system, and STAgora™, a real-time diagnostic analysis platform with predictive capabilities.

With the establishment of the French branch, Seegene now operates eight foreign subsidiaries, bolstering its global distribution network, which encompasses 90 distributors across 94 countries. During the first half of 2025, international sales accounted for around 93% of Seegene’s total revenue, with Europe contributing to 63% of that percentage. This region continues to be a critical growth engine in the company's global expansion strategy.

It is important to note that CURECA™ and STAgora™ are still under development and are not currently available for diagnostic use.

Founded over 25 years ago, Seegene specializes in real-time PCR syndromic testing technologies, proving its expertise particularly evident during the COVID-19 pandemic, when the company delivered over 340 million COVID-19 tests to more than 100 countries worldwide. Seegene's syndrome-based PCR technology allows simultaneous detection of 14 pathogens that present similar clinical signs and symptoms, all within a single reaction tube while providing quantitative information for each pathogen.

For more information, visit Seegene's official website and follow them on LinkedIn.